Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: ValuEngine, Inc.
Provider: Zacks Investment Research Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AcelRx Pharmaceuticals Inc Announces Pricing of Public Offering of Common Stock

Thursday, 18 Jul 2013 09:24am EDT 

AcelRx Pharmaceuticals Inc announced the pricing of its previously announced underwritten public offering of 3.8 million shares of its common stock, offered at a price of $11.65 per share to the public. The gross proceeds to AcelRx from this offering are expected to be approximately $44.27 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by AcelRx. All of the shares in the offering are to be sold by AcelRx. The offering is expected to close on or about July 23, 2013, subject to the satisfaction of customary closing conditions. AcelRx has granted the underwriters a 30-day option to purchase up to an aggregate of 570,000 additional shares of common stock offered in the public offering. Jefferies LLC and Piper Jaffray & Co. acted as joint book-running managers for the offering, and Guggenheim Securities acted as co-manager for the offering. 

Company Quote

-0.27 -3.00%
6 Mar 2015